Clinical Trial Update: Effects of 48 Weeks Versus 24 Weeks of Therapy With Peg-Intron/Ribavirin in Patients With Chronic Hepatitis C, Genotype 3 (Study P04143)(TERMINATED) [Phase 4]

View source ↗

Summary

A Phase 4 study comparing 48 weeks versus 24 weeks of Peg-Intron with ribavirin in chronic hepatitis C (genotype 3) was terminated; results were posted in 2009.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatitis C

Drugs mentioned

• PEG Intron (pegylated interferon alfa-2b)
• Ribavirin (ribavirin)

Snippet

Sponsor: Merck Sharp & Dohme LLC | Conditions: Hepatitis C, Chronic | Phase 4 | Status: TERMINATED | Results posted: 2009-07-23